Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2019

01-10-2019 | Colonoscopy | Research Article

Experience with a colorectal cancer campaign in Swiss pharmacies

Authors: Martine Ruggli, Daniela Stebler, Markus Gasteiger, Maria Trottmann, Philip Hochuli, Harry Telser, Fabian Vaucher

Published in: International Journal of Clinical Pharmacy | Issue 5/2019

Login to get access

Abstract

Background Colorectal cancer is the third most common cancer worldwide. Screening with several methods can accurately detect early-stage cancer and polyps and reduce colorectal cancer mortality in adults aged 50 to 75 years. Objective Test the feasibility, interest and potential impact of a colorectal cancer screening in Swiss community pharmacies. Setting 771 community pharmacies of Switzerland participated in a 6-week campaign. Method The pharmacists evaluated the risk factors through a questionnaire among individuals aged between 50 to 75 years old who did not have had a colonoscopy over the previous 10 years. Pharmacists delivered a Faecal Immunochemical Test (FIT) to those without risk. Patients with identified risk factors or with a positive result were referred to a physician. Patients with a negative result were given lifestyle advice and invited for a new screening in two years. Main outcome measure The impact was measured through the number of persons screened, of tests delivered and of referrals to a physician performed. Results Within 6 weeks, 23,024 persons were screened in pharmacies. In total, 760 patients (3%) had risk factors and were directly referred to physicians. The remaining 22,264 received a FIT, and 97% of these individuals performed and sent the FIT to the laboratory. Of the 21,701 tests analysed, 93% were negative. All individuals with positive results (7%) were referred to a physician. Conclusion Having the opportunity to take colorectal cancer prevention measures with a low threshold, like in a community pharmacy encourages the population to perform the screening.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012v1.0 Cancer Incidence and Mortality Worldwide: IARC Cancerbase No 11. International Agency for Research on Cancer; 2013 [cited 01 March 2019]. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012v1.0 Cancer Incidence and Mortality Worldwide: IARC Cancerbase No 11. International Agency for Research on Cancer; 2013 [cited 01 March 2019].
2.
go back to reference NICER (National Institute for Cancer Epidemiology and Registration) and Federal office of statistics. Schweizerischer Krebsbericht, 2015 Stand und Entwicklung [Swiss cancer report, 2015: state and development]. Zurich: National Institute for Cancer Epidemiology and Registration (CH); 2016 [cited 01 March 2019]. NICER (National Institute for Cancer Epidemiology and Registration) and Federal office of statistics. Schweizerischer Krebsbericht, 2015 Stand und Entwicklung [Swiss cancer report, 2015: state and development]. Zurich: National Institute for Cancer Epidemiology and Registration (CH); 2016 [cited 01 March 2019].
3.
go back to reference Bacchus CM, Dunfield L, Gorber SC, Holmes NM, Birtwhistle R, Dickinson JA, et al. Canadian task force on preventive health care. Recommendations on screening for colorectal cancer in primary care. CMAJ. 2016;188:340–8.CrossRef Bacchus CM, Dunfield L, Gorber SC, Holmes NM, Birtwhistle R, Dickinson JA, et al. Canadian task force on preventive health care. Recommendations on screening for colorectal cancer in primary care. CMAJ. 2016;188:340–8.CrossRef
4.
go back to reference Holme Ø, Bretthauer M, Fretheim A, Odgaard-Jense J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev. 2013;9:CD009259. Holme Ø, Bretthauer M, Fretheim A, Odgaard-Jense J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev. 2013;9:CD009259.
5.
go back to reference Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, González-Navarro A. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366(8):697–706.CrossRef Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, González-Navarro A. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366(8):697–706.CrossRef
6.
go back to reference Lin J, Piper M, Perdue L, Rutter C, Webber E, O’Connor E, et al. Screening for colorectal cancer: a systematic review for the U.S. preventive services task force. Evidence Synthesis No. 135. AHRQ Publication No. 14-05203-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016. Lin J, Piper M, Perdue L, Rutter C, Webber E, O’Connor E, et al. Screening for colorectal cancer: a systematic review for the U.S. preventive services task force. Evidence Synthesis No. 135. AHRQ Publication No. 14-05203-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
7.
go back to reference Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, Arnold D, ESMO Guidelines Working Group. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64–vi72.CrossRef Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, Arnold D, ESMO Guidelines Working Group. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64–vi72.CrossRef
9.
go back to reference Kramis K, Ruckstuhl B, Wyler M. Nationale Strategie gegen Krebs 2014–2017 [National strategy against cancer report]; Bern: Federal Office of Public Health FOPH (CH); 2013 [cited 01 March 2019]. Kramis K, Ruckstuhl B, Wyler M. Nationale Strategie gegen Krebs 2014–2017 [National strategy against cancer report]; Bern: Federal Office of Public Health FOPH (CH); 2013 [cited 01 March 2019].
10.
go back to reference Federal Department of Home Affairs FDHA. Verordnung des EDI über Leistungen in der obligatorischen Krankenpflegeversicherung [Implementation regulation on mandatory health insurance services, Federal Office of Health]. Bern: Federal Council (CH); [cited 01 March 2019]. Federal Department of Home Affairs FDHA. Verordnung des EDI über Leistungen in der obligatorischen Krankenpflegeversicherung [Implementation regulation on mandatory health insurance services, Federal Office of Health]. Bern: Federal Council (CH); [cited 01 March 2019].
11.
go back to reference Fedewa S, Cullati S, Bouchardy C, Welle I, Burton-Jeangros C, Manor O, Guessous I. Colorectal cancer screening in Switzerland: cross-sectional trends (2007–2012) in socioeconomic disparities. PLoS ONE. 2015;10(7):e0131205–e01312050131205.CrossRef Fedewa S, Cullati S, Bouchardy C, Welle I, Burton-Jeangros C, Manor O, Guessous I. Colorectal cancer screening in Switzerland: cross-sectional trends (2007–2012) in socioeconomic disparities. PLoS ONE. 2015;10(7):e0131205–e01312050131205.CrossRef
12.
go back to reference Federal Council of Switzerland. Bericht des Bundesrates in Erfüllung des Postulats Humbel (Nr. 12.3864) vom 27. September 2012: Positionierung der Apotheken in der Grundversorgung [Swiss Federal’s Council’s report in response to the postulate Humbel (12.3864) dated 27 September 2012; Positioning of pharmacies in primary care]. Bern: Federal Council (CH); 2016 [cited 01 March 2019]. Federal Council of Switzerland. Bericht des Bundesrates in Erfüllung des Postulats Humbel (Nr. 12.3864) vom 27. September 2012: Positionierung der Apotheken in der Grundversorgung [Swiss Federal’s Council’s report in response to the postulate Humbel (12.3864) dated 27 September 2012; Positioning of pharmacies in primary care]. Bern: Federal Council (CH); 2016 [cited 01 March 2019].
13.
go back to reference Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink J, van der Togt ACM, Kuipers EJ, Habbema JDF, van Leerdam ME. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer. 2009;100(7):1103–10.CrossRef Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink J, van der Togt ACM, Kuipers EJ, Habbema JDF, van Leerdam ME. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer. 2009;100(7):1103–10.CrossRef
14.
go back to reference Marbet U, Bauerfeind P, Brunner J, Dorta G, Valloton J, Delcò F. Colonoscopy is the preferred colorectal cancer screening method in a population-based program. Endoscopy. 2008;40(08):650–5.CrossRef Marbet U, Bauerfeind P, Brunner J, Dorta G, Valloton J, Delcò F. Colonoscopy is the preferred colorectal cancer screening method in a population-based program. Endoscopy. 2008;40(08):650–5.CrossRef
15.
go back to reference Denters MJ, Deutekom M, Bossuyt PM, Stroobants AK, Fockens P, Dekker E. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology. 2012;142(3):497–504.CrossRef Denters MJ, Deutekom M, Bossuyt PM, Stroobants AK, Fockens P, Dekker E. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology. 2012;142(3):497–504.CrossRef
16.
go back to reference Selby K, Baumgartner C, Levin TR, Doueni CA, Zauber AG, Scottinger J, Jensen CD, Lee JK, Corley A. Interventions to improve follow-up of positive results on fecal blood tests a systematic review. Ann Intern Med. 2017;167:565–75.CrossRef Selby K, Baumgartner C, Levin TR, Doueni CA, Zauber AG, Scottinger J, Jensen CD, Lee JK, Corley A. Interventions to improve follow-up of positive results on fecal blood tests a systematic review. Ann Intern Med. 2017;167:565–75.CrossRef
17.
go back to reference von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45(1):51–9. von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45(1):51–9.
18.
go back to reference Inadomi JM. Screening for colorectal neoplasia. N Engl J Med. 2017;376:149–56.CrossRef Inadomi JM. Screening for colorectal neoplasia. N Engl J Med. 2017;376:149–56.CrossRef
Metadata
Title
Experience with a colorectal cancer campaign in Swiss pharmacies
Authors
Martine Ruggli
Daniela Stebler
Markus Gasteiger
Maria Trottmann
Philip Hochuli
Harry Telser
Fabian Vaucher
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 5/2019
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00899-z

Other articles of this Issue 5/2019

International Journal of Clinical Pharmacy 5/2019 Go to the issue